Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026

Same author

A Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I-III Resectable Rectal Cancer.

Current oncology (Toronto, Ont.)·2026

Same author

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

Neuro-oncology·2026

Same author

Impact of an Electronic Patient-Reported Outcome-Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Randomized Controlled Trial (WF-1805CD).

JCO oncology practice·2025

Same author

Bottom-up sono-enzymatic approach to build antimicrobial and antifouling nano-enabled coatings on urinary catheters.

Nanoscale advances·2025

Same author

Cognitive Performance in Patients With Multiple Myeloma Treated With an Autologous Stem Cell Transplant: Results of the Brilliant Study.

Clinical lymphoma, myeloma & leukemia·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Phase I study of lenalidomide in solid tumors.

Antonius A Miller¹, Doug Case, Michele Harmon

¹Wake Forest University, Comprehensive Cancer Center, Winston-Salem, NC 27157, USA. aamiller@wfubmc.edu

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer

|May 3, 2007

Summary

This Phase I study determined the tolerable dose of lenalidomide for solid tumors. The recommended dose is 25 mg/day for 4 weeks followed by a 2-week rest, with manageable toxicity.

Related Experiment Videos

Last Updated: Jul 15, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Area of Science:

Oncology
Clinical Pharmacology

Background:

Phase I clinical trial investigating lenalidomide in solid tumors refractory to standard treatment.
Focus on defining tolerable dose and toxicity profile for a novel dosing schedule.

Purpose of the Study:

Determine the maximum tolerated dose (MTD) of lenalidomide.
Evaluate the safety and tolerability of lenalidomide.
Assess preliminary antitumor activity.

Main Methods:

Oral lenalidomide administered at 5, 10, and 25 mg/day in a 4-week on, 2-week off schedule.
Dose escalation based on toxicity, with dose-limiting toxicity defined by specific criteria.
Eligibility included performance status 0-2 and adequate organ function.

Main Results:

Twenty patients enrolled; 12 received 25 mg/day.
One dose-limiting toxicity (grade 3 motor neuropathy) observed at 25 mg/day.
Generally mild to moderate, reversible hematologic and non-hematologic toxicities.

Conclusions:

The recommended Phase II dose for lenalidomide in solid tumors is 25 mg/day.
The 4-week on, 2-week off schedule is tolerable with manageable toxicity.
Preliminary evidence of antitumor activity, including partial response in one patient.